Highlights from ASCO
June 5, 2023
Dr Claudio Cerchione summarised the educational session on the management of multiple myeloma in special patient populations, such as elderly and patients with renal failure.
From 2 June till 6 June 2023: HIGHLIGHTS FROM ASCO
Your direct line with Chicago
The American Society of Clinical Oncology (ASCO) 2023 brings together leading experts in the different fields of cancer from around the world. And, as usual, they gather together in Chicago, USA. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
With the support of:
Daily highlights
Project in the spotlight
Updates from GMMG-HD7
December 19, 2024
In this video, Dr Elias Mai, haematologist at the Heidelberg University Hospital in Germany and one of the lead investigator of GMMG-HD7, shares the key take-aways of these abstracts.
Five-year follow-up of the phase II OPTIC study
December 19, 2024
In this video, Prof Jorge Cortes, haematologist at the Georgia Cancer Centre in Augusta, Georgia (USA), discusses the 5-year follow up data of this trial presented at ASH 2024.
Frontline ponatinib plus blinatumomab for Ph+ ALL
December 18, 2024
In this video, Prof Robin Foà, emeritus professor of haematology at the Sapienza University of Rome discusses two abstracts presented at ASH zooming in on the use of ponatinib plus
Updates from the EAE115 and IONA-MM studies
December 18, 2024
In this video, Prof Fredrik Schjesvold, head of the Oslo myeloma center in Oslo (Norway), discusses the results of the EAE 115 study evaluating this regimen as a second line
MRD negativity dynamics in the IMROZ study
December 16, 2024
Dr Robert Orlowski, a haematologist at the University of Texas MD Anderson Cancer Center in Houston, Texas, provided a comprehensive summary of his presentation on MRD testing in the context
inMIND study in R/R follicular lymphoma
December 13, 2024
Prof Marek Trneny, haematologist at Charles University General Hospital in Prague, Czech Republic, presented findings from the inMIND study, featured as a late-breaking abstract at the ASH meeting.
DREAMM-7 study in R/R MM
December 13, 2024
Prof Dr Claudio Cerchione, a haematologist at the Istituto Romagnolo per lo Studio dei Tumori in Meldola, Italy, co-authored the DREAMM-7 study and shared updated efficacy data presented at ASH
AALL1731 trial
December 12, 2024
Dr Sumit Gupta, a paediatric oncologist and assistant professor at the Hospital for Sick Children and the University of Toronto, Canada, presented the main findings of the AALL1731 study, of
In-depth stories
Updates from GMMG-HD7
December 19, 2024
In this video, Dr Elias Mai, haematologist at the Heidelberg University Hospital in Germany and one of the lead investigator of GMMG-HD7, shares the key take-aways of these abstracts.
Five-year follow-up of the phase II OPTIC study
December 19, 2024
In this video, Prof Jorge Cortes, haematologist at the Georgia Cancer Centre in Augusta, Georgia (USA), discusses the 5-year follow up data of this trial presented at ASH 2024.
Frontline ponatinib plus blinatumomab for Ph+ ALL
December 18, 2024
In this video, Prof Robin Foà, emeritus professor of haematology at the Sapienza University of Rome discusses two abstracts presented at ASH zooming in on the use of ponatinib plus
Updates from the EAE115 and IONA-MM studies
December 18, 2024
In this video, Prof Fredrik Schjesvold, head of the Oslo myeloma center in Oslo (Norway), discusses the results of the EAE 115 study evaluating this regimen as a second line
MRD negativity dynamics in the IMROZ study
December 16, 2024
Dr Robert Orlowski, a haematologist at the University of Texas MD Anderson Cancer Center in Houston, Texas, provided a comprehensive summary of his presentation on MRD testing in the context
inMIND study in R/R follicular lymphoma
December 13, 2024
Prof Marek Trneny, haematologist at Charles University General Hospital in Prague, Czech Republic, presented findings from the inMIND study, featured as a late-breaking abstract at the ASH meeting.
DREAMM-7 study in R/R MM
December 13, 2024
Prof Dr Claudio Cerchione, a haematologist at the Istituto Romagnolo per lo Studio dei Tumori in Meldola, Italy, co-authored the DREAMM-7 study and shared updated efficacy data presented at ASH
AALL1731 trial
December 12, 2024
Dr Sumit Gupta, a paediatric oncologist and assistant professor at the Hospital for Sick Children and the University of Toronto, Canada, presented the main findings of the AALL1731 study, of
Poster selection
A dual Role of SOX11 expression in the formation of T-cell ALL in mouse models
December 11, 2023
André De Almeida, PhD student at the University Hospital Ghent presented his research on investigating the role of SOX11 in T-ALL, which is motivated by its expression within a distinct
A 46 long non-coding RNAs expression signature as independent prognostic factor in pediatric AML
December 10, 2023
Approximately 30% of pediatric AML patients encounter relapse, emphasizing the imperative need for refining risk stratification in this cohort. Consequently, Zhiyao Ren, PhD student at University Hospital Ghent, constructed a
Results from the Phase 1/2 Atalanta-1 trial
December 10, 2023
An innovative decentralized and automated PoC manufacturing paradigm was devised to facilitate the expeditious administration of freshly prepared autologous CAR-T therapies within a 7-day timeframe following apheresis in patients diagnosed
The REST study
December 10, 2023
Dr Frida Bugge Askeland, associated research doctor and PhD student at the Oslo Myeloma Center in Norway summarised the REST study.
In Norway, the use of VRd (bortezomib, lenalidomide
Brain radiotherapy for progressive secondary CNS lymphoma
June 23, 2023
Dr. Gustav Cederquist from the Memorial Sloan Kettering Cancer Center, New Yorkevaluated the potential of brain radiotherapy as an effective bridge for chemo-refractory or progressive secondary CNS lymphoma.
Impact of the dark zone signature on CNS relapse
June 23, 2023
Central nervous system (CNS) relapse in diffuse large B-cell lymphoma is associated with poor outcomes necessitating the identification of high-risk patients. To refine CNS risk stratification, a better understanding of
Enteropathy associated T-cell lymphoma
June 23, 2023
Enteropathy associated T-cell lymphoma is a rare peripheral T-cell lymphoma with a poor prognosis. Dr. Frederik Meeuwes, hematologist from the Treant hospital in Emmen presented a population-based cohort study on
Impact of MYC-R on the outcome of LS DLBCL patients
June 23, 2023
Vera De Jonge, PhD student from the VUMC, Amsterdam and Joanna Bult, PhD student from the University Medical Center Groningen assessed the impact of a rearrangement of the MYC oncogene